Anti-Hypertensive Drugs - Netherlands

Netherlands

The Anti-Hypertensive Drugs market in the Netherlands is expected to experience significant growth in the coming years.
According to projections, the market's revenue is set to reach €104.80m in 2024.
Furthermore, it is anticipated that the market will continue to expand at a compound annual growth rate (CAGR 2024-2029) of -0.37%, resulting in a market volume of €102.90m by 2029.
When compared to other countries globally, United States is expected to generate the highest revenue in the Anti-Hypertensive Drugs market, with a projected revenue of €11,280.00m in 2024.
The Netherlands is experiencing a growing demand for innovative anti-hypertensive drugs due to the country's aging population and high prevalence of hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Hypertensive Drugs market in Netherlands has been steadily growing in recent years.

Customer preferences: Patients in Netherlands have been increasingly seeking out medication for hypertension due to the rising prevalence of the condition in the country. As a result, there has been a growing demand for anti-hypertensive drugs in the market. Additionally, the preference for generic drugs has also been on the rise in the country due to their lower cost.

Trends in the market: One of the major trends in the Anti-Hypertensive Drugs market in Netherlands has been the increasing use of combination therapies. Physicians in the country have been prescribing combinations of different classes of anti-hypertensive drugs to achieve better blood pressure control in patients. Another trend in the market has been the growing use of fixed-dose combination drugs, which simplify the treatment regimen for patients and improve medication adherence.

Local special circumstances: The healthcare system in Netherlands is highly regulated, with a focus on cost containment. This has led to a highly competitive market for pharmaceutical companies, with a strong emphasis on the cost-effectiveness of drugs. Additionally, the country has a well-established system for monitoring the safety and effectiveness of drugs, which has helped to build trust in the healthcare system and promote the use of anti-hypertensive drugs among patients.

Underlying macroeconomic factors: The aging population in Netherlands has been a major driver of the growth in the Anti-Hypertensive Drugs market. As people age, they become more susceptible to hypertension, leading to a higher demand for medication. Additionally, the country's strong economy and high per capita income have allowed for increased healthcare spending, including on anti-hypertensive drugs. However, the increasing prevalence of hypertension in the country has also put pressure on the healthcare system to provide affordable and effective treatment options for patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.